Literature DB >> 17991715

Expression microarray analysis implicates apoptosis and interferon-responsive mechanisms in susceptibility to experimental cerebral malaria.

Fiona E Lovegrove1, Sina A Gharib, Samir N Patel, Cheryl A Hawkes, Kevin C Kain, W Conrad Liles.   

Abstract

Specific local brain responses, influenced by parasite sequestration and host immune system activation, have been implicated in the development of cerebral malaria. This study assessed whole-brain transcriptional responses over the course of experimental cerebral malaria by comparing genetically resistant and susceptible inbred mouse strains infected with Plasmodium berghei ANKA. Computational methods were used to identify differential patterns of gene expression. Overall, genes that showed the most transcriptional activity were differentially expressed in susceptible mice 1 to 2 days before the onset of characteristic symptoms of cerebral malaria. Most of the differentially expressed genes identified were associated with immune-related gene ontology categories. Further analysis to identify interaction networks and to examine patterns of transcriptional regulation within the set of identified genes implicated a central role for both interferon-regulated processes and apoptosis in the pathogenesis of cerebral malaria. Biological relevance of these genes and pathways was confirmed using quantitative RT-PCR and histopathological examination of the brain for apoptosis. The application of computational biology tools to examine systematically the disease progression in cerebral malaria can identify important transcriptional programs activated during its pathogenesis and may serve as a methodological approach to identify novel targets for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17991715      PMCID: PMC2111112          DOI: 10.2353/ajpath.2007.070630

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  73 in total

1.  C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria.

Authors:  Elke S Bergmann-Leitner; Sandra Scheiblhofer; Richard Weiss; Elizabeth H Duncan; Wolfgang W Leitner; Defeng Chen; Evelina Angov; Farhat Khan; Jackie L Williams; David B Winter; Josef Thalhamer; Jeffrey A Lyon; George C Tsokos
Journal:  Int Immunol       Date:  2005-02-14       Impact factor: 4.823

2.  A role for Fas-Fas ligand interactions during the late-stage neuropathological processes of experimental cerebral malaria.

Authors:  Sarah M Potter; Tailoi Chan-Ling; Emilia Rosinova; Helen J Ball; Andrew J Mitchell; Nicholas H Hunt
Journal:  J Neuroimmunol       Date:  2006-01-18       Impact factor: 3.478

3.  Protection against the mortality associated with disease models mediated by TNF and IFN-gamma in mice lacking IFN regulatory factor-1.

Authors:  G Senaldi; C L Shaklee; J Guo; L Martin; T Boone; T W Mak; T R Ulich
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

4.  Common and divergent immune response signaling pathways discovered in peripheral blood mononuclear cell gene expression patterns in presymptomatic and clinically apparent malaria.

Authors:  Christian F Ockenhouse; Wan-chung Hu; Kent E Kester; James F Cummings; Ann Stewart; D Gray Heppner; Anne E Jedlicka; Alan L Scott; Nathan D Wolfe; Maryanne Vahey; Donald S Burke
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

5.  Polymorphisms of transporter associated with antigen processing type 1 (TAP1), proteasome subunit beta type 9 (PSMB9) and their common promoter in African children with different manifestations of malaria.

Authors:  S Niesporek; C G Meyer; P G Kremsner; J May
Journal:  Int J Immunogenet       Date:  2005-02       Impact factor: 1.466

Review 6.  Breaking down the blood-brain barrier: signaling a path to cerebral malaria?

Authors:  Sue Adams; Heidi Brown; Gareth Turner
Journal:  Trends Parasitol       Date:  2002-08

7.  Identifying biological themes within lists of genes with EASE.

Authors:  Douglas A Hosack; Glynn Dennis; Brad T Sherman; H Clifford Lane; Richard A Lempicki
Journal:  Genome Biol       Date:  2003-09-11       Impact factor: 13.583

8.  Recombinant human IFN-alpha inhibits cerebral malaria and reduces parasite burden in mice.

Authors:  Ana Margarida Vigário; Elodie Belnoue; Anne Charlotte Grüner; Marjorie Mauduit; Michèle Kayibanda; Jean-Christophe Deschemin; Myriam Marussig; Georges Snounou; Dominique Mazier; Ion Gresser; Laurent Rénia
Journal:  J Immunol       Date:  2007-05-15       Impact factor: 5.422

9.  The lack of suppressor of cytokine signalling-1 (SOCS1) protects mice from the development of cerebral malaria caused by Plasmodium berghei ANKA.

Authors:  Denise V R Bullen; Diana S Hansen; Mary-Anne V Siomos; Louis Schofield; Warren S Alexander; Emanuela Handman
Journal:  Parasite Immunol       Date:  2003-03       Impact factor: 2.280

Review 10.  Neurological sequelae of cerebral malaria in children.

Authors:  D R Brewster; D Kwiatkowski; N J White
Journal:  Lancet       Date:  1990-10-27       Impact factor: 79.321

View more
  36 in total

1.  Disease and phenotype gene set analysis of disease-based gene expression in mouse and human.

Authors:  Supriyo De; Yongqing Zhang; John R Garner; S Alex Wang; Kevin G Becker
Journal:  Physiol Genomics       Date:  2010-08-03       Impact factor: 3.107

2.  Cerebral malaria pathogenesis: what can we learn from microarray analysis?

Authors:  Chandy C John
Journal:  Am J Pathol       Date:  2007-11-08       Impact factor: 4.307

Review 3.  Host resistance to malaria: using mouse models to explore the host response.

Authors:  Rhea Longley; Clare Smith; Anny Fortin; Joanne Berghout; Brendan McMorran; Gaétan Burgio; Simon Foote; Philippe Gros
Journal:  Mamm Genome       Date:  2010-11-30       Impact factor: 2.957

4.  Oral activated charcoal prevents experimental cerebral malaria in mice and in a randomized controlled clinical trial in man did not interfere with the pharmacokinetics of parenteral artesunate.

Authors:  J Brian de Souza; Uduak Okomo; Neal D Alexander; Naveed Aziz; Benjamin M J Owens; Harparkash Kaur; Momodou Jasseh; Sant Muangnoicharoen; Percy F Sumariwalla; David C Warhurst; Stephen A Ward; David J Conway; Luis Ulloa; Kevin J Tracey; Brian M J Foxwell; Paul M Kaye; Michael Walther
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

5.  Predominance of interferon-related responses in the brain during murine malaria, as identified by microarray analysis.

Authors:  Jenny Miu; Nicholas H Hunt; Helen J Ball
Journal:  Infect Immun       Date:  2008-02-25       Impact factor: 3.441

6.  Noninjurious mechanical ventilation activates a proinflammatory transcriptional program in the lung.

Authors:  Sina A Gharib; W Conrad Liles; Lindy S Klaff; William A Altemeier
Journal:  Physiol Genomics       Date:  2009-03-10       Impact factor: 3.107

7.  Eimeria falciformis infection of the mouse caecum identifies opposing roles of IFNγ-regulated host pathways for the parasite development.

Authors:  Manuela Schmid; Emanuel Heitlinger; Simone Spork; Hans-Joachim Mollenkopf; Richard Lucius; Nishith Gupta
Journal:  Mucosal Immunol       Date:  2013-12-25       Impact factor: 7.313

8.  Over-expression and localization of a host protein on the membrane of Cryptosporidium parvum infected epithelial cells.

Authors:  Yi-Lin Yang; Myrna G Serrano; Abhineet S Sheoran; Patricio A Manque; Gregory A Buck; Giovanni Widmer
Journal:  Mol Biochem Parasitol       Date:  2009-07-22       Impact factor: 1.759

9.  Cerebral malaria in children is associated with long-term cognitive impairment.

Authors:  Chandy C John; Paul Bangirana; Justus Byarugaba; Robert O Opoka; Richard Idro; Anne M Jurek; Baolin Wu; Michael J Boivin
Journal:  Pediatrics       Date:  2008-06-09       Impact factor: 7.124

10.  Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.

Authors:  Peter Lackner; Andrea Part; Christoph Burger; Anelia Dietmann; Gregor Broessner; Raimund Helbok; Markus Reindl; Erich Schmutzhard; Ronny Beer
Journal:  Malar J       Date:  2009-02-27       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.